Pratt & Whitney has successfully completed the Risk Reduction Design Review for the F135 Engine Core Upgrade, a critical step validating the engine's design maturity and readiness for production. This upgrade enhances power and thermal management to support advanced sensors and weapons for all F-35 variants, enabling Block 4 and future capabilities. The program is on track to improve fleet readiness and provide a cost-effective modernization path, with the upgrade designed as a drop-in solution for new and existing aircraft. Pratt & Whitney continues to support a global F-35 fleet with over 1,500 engines delivered to 20 allied nations.
Pratt & Whitney's F135 Engine Core Upgrade is the subject, with this Pluang market snapshot for Industrials-sector US stocks as of Sep 15, 2026 16:51 WIB: Of 75 stocks, only 17 rose while 52 fell. Notably, TECK was priced at USD 63.98 with a 1-day change of -3.43%, contrasting with SBLK at USD 29.99 down 2.72%, and EH at USD 4.42 down 2.00%.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
